These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19589730)

  • 1. Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself.
    Schlingmann TR; Rininsland FH; Bartholomae WC; Kuekrek H; Lehmann PV; Tary-Lehmann M
    Clin Immunol; 2009 Oct; 133(1):45-51. PubMed ID: 19589730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-expression of immunogenic determinants by the same cellular immunogen is required for the optimum immunotherapeutic benefit in mice with melanoma.
    Xu W; de Zoeten E; Carr-Brendel V; Cohen EP
    Cancer Immunol Immunother; 1998 Jan; 45(5):217-24. PubMed ID: 9439644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
    Assudani D; Cho HI; DeVito N; Bradley N; Celis E
    Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
    Fischer C; Munks MW; Hill AB; Kroczek RA; Bissinger S; Brand V; Schmittnaegel M; Imhof-Jung S; Hoffmann E; Herting F; Klein C; Knoetgen H
    MAbs; 2020; 12(1):1834818. PubMed ID: 33151105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.
    Cho HI; Celis E
    Cancer Immunol Immunother; 2012 Mar; 61(3):343-51. PubMed ID: 21915800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.
    Cerkovnik P; Novakovic BJ; Stegel V; Novakovic S
    BMC Immunol; 2010 Sep; 11():45. PubMed ID: 20836870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity.
    Neal ZC; Bates MK; Albertini MR; Herweijer H
    Mol Ther; 2007 Feb; 15(2):422-30. PubMed ID: 17235322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax.
    Mansour M; Pohajdak B; Kast WM; Fuentes-Ortega A; Korets-Smith E; Weir GM; Brown RG; Daftarian P
    J Transl Med; 2007 Apr; 5():20. PubMed ID: 17451606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ T cell protective immunity against Chlamydia pneumoniae includes an H2-M3-restricted response that is largely CD4+ T cell-independent.
    Tvinnereim A; Wizel B
    J Immunol; 2007 Sep; 179(6):3947-57. PubMed ID: 17785832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
    Nair SK; Boczkowski D; Snyder D; Gilboa E
    Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
    Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
    Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.